Journal article

Comparison of ER, PR & HER2/neu(C-erb B2) reactivity pattern with various histomorphological patterns in patients with breast cancer

AMAlpesh M. Maru AMAlpesh M. Maru ASAtul Shrivastava ASAtul Shrivastava TCTejas Chokshi TCTejas Chokshi AAA. S. Agnihotri AAA. S. Agnihotri
Year0
Volume3
Issue4
Pages241-247
Article Details

Abstract

Introduction: Globally carcinoma breast is the leading cause of cancer death in women .Prognosis of such patients is related to a variety of Histomorphological features which includes, Histological grade, type, tumor size and lymph node metastases. Estrogen and progesterone receptors (ER, PR) and more recently, HER-2/neu have with increasing importance influenced the management of the malignancy.
Materials and Methods: This study was carried out at tertiary care hospital which included 70 cases of breast cancer that we have reported at our department during a period from June 2012 to June 2014.Specimens were fixed overnight in 10% Neutral buffered formalin and processed as routine for H&E staining. Representative sections with tumour with adjacent normal breast tissue (internal control) were taken on Poly-L-Lysine coated slides and proceed for antigen retrieval, HRP Polymerization steps and than processed for ER, PR and HER-2/neu immuno-histochemical staining with respective antibody.
Observation and Results: Maximum No. Of cases were in age group 5th and 6th decade with Invasive ductal carcinoma was predominately observed followed by invasive lobular carcinoma. Among 70 cases, 25 cases (35.71%) showing ER/PR+ HER 2- pattern which is predominant pattern in this study. While 23 cases (32.85%) showing Tripple negative pattern.
Conclusion: most important cost effective, prognostic markers are estrogen receptor status, progesterone receptor status and HER2/neu status. Correlation of these marker status with clinical parameters helps in predicting the future treatment modalities and disease free survival for the patient in developing countries.

Keywords: ER-Estrogen receptor, PR-Progesteron recptor, Immunohistochemistry.

Cite this article

Citation data